AXIN2 and colorectal cancer: Inactivating GNAI2 alterations occur in about 6% of colorectal cancer patients, which is about the frequency of oncogenic β-catenin (5%) or conductin (7%) mutations but far below the loss of APC (77%), the major tumor suppressor of the Wnt pathway2.